Current Report Filing (8-k)
04 September 2019 - 10:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________________________
FORM 8-K
___________________________
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): September 4, 2019
___________________________
AVID
BIOSERVICES, INC.
(Exact name of registrant as
specified in its charter)
Delaware
|
001-32839
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
2642 Michelle Drive, Suite 200, Tustin, California 92780
|
(Address of Principal Executive Offices)
|
Registrant’s telephone
number, including area code: (714) 508-6100
_____________________________________________________________
(Former name or former address, if changed since last
report)
___________________________
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
☐
|
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each Class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
CDMO
|
The NASDAQ Stock Market LLC
|
Preferred
Stock Purchase Rights
|
–
|
–
|
10.50% Series E Convertible Preferred Stock, $0.001 par value per share
|
CDMOP
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
☐
|
Emerging growth company
|
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On September 4, 2019,
Avid Bioservices, Inc. (the “Company”) issued a press release announcing the declaration by the Company’s Board
of Directors of a quarterly cash dividend payment of $0.65625 per share (the “Dividend”) on the Company’s 10.50%
Series E Convertible Preferred Stock (the “Series E Preferred Stock”), accruing from July 1, 2019 through September
30, 2019. The Dividend equates to an annualized 10.50% per share of Series E Preferred Stock based on the $25.00 per share stated
liquidation preference. The Dividend on the Series E Preferred Stock is payable on October 1, 2019 to holders of record at the
close of business on September 16, 2019. A copy of the press release is filed hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following material is
filed as an exhibit to this Current Report on Form 8-K:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AVID BIOSERVICES, INC.
|
|
|
|
|
|
|
Date: September 4, 2019
|
By: /s/ Daniel R.
Hart
|
|
Daniel R. Hart
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
|
|
Number
|
Description
|
|
|
99.1
|
Press Release issued September 4, 2019.
|
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jul 2023 bis Jul 2024